Compare · HCXY vs IBBJ
HCXY vs IBBJ
Side-by-side comparison of Hercules Capital, Inc. (HCXY) and Defiance Nasdaq Junior Biotechnology ETF (IBBJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HCXY and IBBJ operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.55B.
- HCXY has hit the wire 5 times in the past 4 weeks while IBBJ has been quiet.
Defiance Nasdaq Junior Biotechnology ETF
The investment seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index. The index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization ("junior") companies screened from the universe of the NASDAQ Biotechnology Index. The fund will generally use a "replication" strategy to achieve its investment objective, meaning it will generally invest in all of the component securities of the index in the same approximate proportions as in the index. The fund is non-diversified.
Latest HCXY
- Hercules Capital Reports Second Quarter 2026 Financial Results
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026
- Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031
- Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031
- Hercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference Call
- Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
- Hercules Capital Reports First Quarter 2026 Financial Results
- Hercules Capital Enters Next Phase of Growth with Expanded Leadership Team
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the First Quarter 2026
- Hercules Capital Announces Date for Release of First Quarter 2026 Financial Results and Conference Call